Alanh Auerbach News Today

Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2023. Unless otherwise stated, all comparisons are for the...

Transition to Profitability Amidst Operational Adjustments and Clinical Developments

Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will attend TD Cowen’s 44th Annual Health...

HC Wainwright reiterated their buy rating on shares of Puma Biotechnology (NASDAQ:PBYI – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. They currently have a $8.00 price target on the biopharmaceutical company’s stock. Separately, StockNews.com upgraded shares of Puma Biotechnology from a buy rating to a strong-buy rating in a […]

Puma Biotechnology, Inc. , a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA-Lung1) Phase II trial (PUMA-ALI-4201; NCT06095505) of alisertib monotherapy for the treatment of patients with extensive stage small...

Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.52 and traded as high as $5.16. Puma Biotechnology shares last traded at $4.71, with a volume of 749,465 shares trading hands. Wall Street Analyst Weigh In Separately, […]

Puma Biotechnology, Inc. , a biopharmaceutical company , announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company on...

Puma Biotechnology, Inc. , a biopharmaceutical company , announced the design of the Phase II trial of alisertib for the treatment of patients with HER2-negative, hormone receptor-positive metastatic...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2023. Unless otherwise stated, all comparisons are for the third quarter of 2023 compared to the third quarter of 2022.Product revenue, net consist...

Puma Biotechnology, Inc. , a biopharmaceutical company, announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the treatment of patients with Rb-deficient head...